<DOC>
	<DOCNO>NCT02900001</DOCNO>
	<brief_summary>This study evaluate efficacy safety early invasive strategy routine delay invasive strategy Chinese elderly patient 75 year old non-ST elevation myocardial infarction , verify hypothesis routine delay invasive strategy inferior early invasive strategy group patient .</brief_summary>
	<brief_title>Delayed Versus EARly Invasive Strategy Patients 75 Years OLDer With Non-ST-elevation Myocardial Infarction</brief_title>
	<detailed_description>This study aim enroll 520 elderly patient non-ST elevation myocardial infarction ( NSTEMI ) . Patients identify screen elderly patient 75 year older elevate cardiac troponin ischemic change electrocardiogram 20 hospital throughout China . Written inform consent form obtain patient whose onset symptom within 48 hour admission . When patient consent participate study , brief information enter central randomization system , random number generate . According random number , patient randomly assign early invasive therapy versus routine delay invasive strategy . All patient initiate dual antiplatelet therapy ( aspirin+P2Y12 inhibitor ) continue till end follow-up one year . For patient assign early invasive group , load dose antiplatelet agent give , unless contraindicate . Anticoagulation , anti-ischemic agent , statin guideline recommend medicine give accord treat physician . Patients assign early invasive strategy undergo coronary angiography within 24 hour admission percutaneous coronary intervention coronary artery bypass graft soon possible index hospitalization appropriate . Patients assign delayed invasive strategy undergo coronary angiography appropriate revascularization 72 hour l admission index hospitalization . Patients undergo percutaneous coronary intervention receive glycoprotein IIb/IIIa inhibitor indicate upfront use glycoprotein IIb/IIIa inhibitor discourage . The choice intervention surgery choice complete stag revascularization determine operator accord coronary anatomy consistent current practice guideline . Patients assign delayed strategy undertake urgent coronary angiography revascularization accordingly indicated period time wait delay invasive therapy . Such procedure adjudicate endpoint . Elective percutaneous coronary intervention non-culprit vessel , either study arm , take place sometime index procedure goal achieve complete revascularization . Such staged procedure deem adverse event . Specific data acquisition : Research demographic : age , height , weight , body mass index , medication randomization , pertinent medical/family/social history , i.e. , hypertension , hypercholesterolemia , diabetes mellitus , current tobacco use , history prior myocardial infarction , PCI CABG . This data gather research coordinator interview patient check patient 's medical record . Procedural : Exact time onset ischemic symptom , admission , randomization , undertake coronary angiography note supplemental chart , along important information like evidence occurrence endpoint . Blood concentration hemoglobin , BNP/NT-proBNP , creatinine , cardiac troponin C-reaction protein test admission . First electrocardiography echocardiography record . Thrombolysis In Myocardial Infarction flow record PCI procedure , image copy calculate SYNTAX score afterwards . After hospital discharge , research coordinator contact patient specify interval （30 day discharge , 180 day 365 day randomization） determine endpoint meet .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Aged 75 year old 2 . Newly onset ischemic symptom within 48 hour ; 3 . Elevated troponin T/I ; 4 . STsegment depression ( ≥ 0.5 mm ) ; 5 . Written Informed Consent obtain . 1 . Type 2 myocardial infarction ; 2 . Secondary elevation cardiac troponin ; 3 . STelevation myocardial infarction ; 4 . Cardiogenic shock ; 5. refractory congestive heart failure ; 6. hemodynamic instability ; 7. malignant arrhythmia ; 8. cardiac arrest episode ; 9. concomitant use oral anticoagulant ; 10 . PCI/CABG within 30 day ; 11 . Allergy contrast agent ; 12. serum creatinine ≥2.5mg/dl ; 13. contraindication dual antiplatelet treatment ; 14 . Crusade bleed score ≥50 ; 15. active bleed bleeding diathesis ; 16. clinically relevant bleed gastrointestinal genitourinary system ; 17 . Recent operation trauma ; 18. stroke within 3 month ; 19 . Platelet count &lt; 90×109／L ; 20. comorbidities severe COPD , infectious disease malignant tumor mental defect ; 21. life expectancy &lt; 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>invasive strategy</keyword>
	<keyword>elderly</keyword>
	<keyword>delayed</keyword>
</DOC>